ListarFHEFD - Contribuciones a congresos científicos por tema "Parkinson's disease"
Mostrando ítems 1-5 de 5
-
A model of increased impulsivity in rats with bilateral parkinsonism treated with Pramipexole
Gago-Calderón, Belén
; Jiménez-Urbieta, Haritz; Marín, Concepció; Quiroga-Varela, Ana; Delgado-Alvarado, Manuel; Rodríguez-Oroz, María Cruz[et al.] (2016)
Impulse control disorders (ICD) is a common side effect of the dopaminergic treatment in patients with Parkinson's disease, which is more associated with dopamine agonists than with levodopa. To understand its pathophysiology, ... -
Different susceptibility to pramipexole-induced impulsivity in a rat model of parkinson’s disease
Jiménez-Urbieta, Haritz; Merino-Galan, Leire; Rodriguez-Chinchilla, Tatiana; Belloso-Iguerategui, Arantzatzu; Delgado-Alvarado, Manuel; Navalpotro-Gómez, Irene; Quiroga-Varela, Ana; Gago-Calderón, Belén; Rodríguez-Oroz, María Cruz[et al.] (2019-09-12)
Impulse Control Disorders (ICD) in patients with Parkinson’s disease are abnormal behaviors caused by long-term use of dopamine agonists, which pathophysiology is poorly understood. Using parkinsonian rats (adeno-associated ... -
Graphene derivative scaffolds facilitate in vitro cell survival and maturation of dopaminergic SN4741 cells
Rodríguez-Losada, Noela; Wendelbo, Rune; García-Fernández, María Inmaculada; Pavía-Molina, José; Martinez-Montañez, Elisa; Lara-Muñoz, José Pablo; Arenas, Ernest; Aguirre-Gómez, José Ángel[et al.] (2014-11-26)
The emerging carbon nanomaterial Graphene (G), in the form of scaffold structure, has an efficient bioconjugation with common biomolecules and activates cell differentiation of neuronal stem cells, providing a promising ... -
IGF-II treatment prevents the oxidative damage derived by MPP+/MPTP administration in a cellular and animal model of Parkinson’s disease.
Zamorano-González, Pablo; Valverde, Nadia; Claros-Gil, Silvia; López-González, Manuel Víctor; Romero-Zerbo, Silvana Yanina; Lara, Estrella; Boraldi, Federica; Pavía-Molina, José; García-Fernández, María Inmaculada; Gago-Calderón, Belén; Martín-Montañez, Elisa[et al.] (2023)
El factor de crecimiento de la insulina-II (IGF-II) ha mostrado efectos antioxidantes y neuroprotectores en algunos trastornos neurodegenerativos, como es la Enfermedad de Parkinson (EP). Analizamos el efecto de IGF-II ... -
Role of Insulin-Growth Factor II on mitochondrial recovery in a cellular model of Parkinson's Disease
Valverde, Nadia; Romero-Zerbo, Silvana Yanina; Lara, Estrella; Claros-Gil, Silvia; Pavía-Molina, José; Martín-Montañez, Elisa; García-Fernández, María Inmaculada[et al.] (Journal of Physiology and Biochemistry, 2022-09)
Insulin-growth factor II (IGF-II) has shown antioxidant and neuroprotective effects in some neurodegenerative disorders. ROS causes damage to cellular macromolecules affecting several cellular processes and resulting in ...